Scholarlink

Purpose <p>To critically evaluate oligoprogression in advanced gastric and gastroesophageal junction (GEJ) cancer and propose a practical multidisciplinary framework integrating local therapy, systemic treatment decisions, and biomarker reassessment.</p> Methods <p>We reviewed direct gastric/GEJ evidence and clearly distinguished it from evidence extrapolated from oligometastatic disease and other tumor types.</p> Results <p>No prospective comparative study has demonstrated that local treatment with continuation of systemic therapy improves survival specifically in gastric/GEJ oligoprogression. In carefully selected patients, local treatment may be considered to delay the next systemic therapy, prevent or relieve symptoms, maintain local control, or preserve quality of life. Tissue rebiopsy or circulating tumor DNA analysis may be useful when technically obtainable and likely to change management. HER2 reassessment has established clinical relevance after HER2-directed treatment, whereas repeat assessment of CLDN18.2, PD-L1, FGFR2b, and other emerging targets remains exploratory. A negative plasma circulating tumor DNA result does not exclude resistant disease, particularly in low-volume, peritoneal, or central nervous system progression.</p> Conclusion <p>Management should remain individualized and multidisciplinary, with explicit recognition that the proposed framework is provisional and that a survival benefit from local therapy with systemic treatment continuation remains unproven.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Oligoprogression in Advanced Gastric and Gastroesophageal Junction Cancer: Integrating Local Therapy, Systemic Treatment Continuation, and Biomarker Reassessment

  • 期刊论文

  • 发表日期：

    2026年7月30日

查看全文
  • Tamotsu Sagawa,
  • Masahiro Hirakawa,
  • Hiroyuki Nagashima,
  • Koshi Fujikawa

摘要

Purpose

To critically evaluate oligoprogression in advanced gastric and gastroesophageal junction (GEJ) cancer and propose a practical multidisciplinary framework integrating local therapy, systemic treatment decisions, and biomarker reassessment.

Methods

We reviewed direct gastric/GEJ evidence and clearly distinguished it from evidence extrapolated from oligometastatic disease and other tumor types.

Results

No prospective comparative study has demonstrated that local treatment with continuation of systemic therapy improves survival specifically in gastric/GEJ oligoprogression. In carefully selected patients, local treatment may be considered to delay the next systemic therapy, prevent or relieve symptoms, maintain local control, or preserve quality of life. Tissue rebiopsy or circulating tumor DNA analysis may be useful when technically obtainable and likely to change management. HER2 reassessment has established clinical relevance after HER2-directed treatment, whereas repeat assessment of CLDN18.2, PD-L1, FGFR2b, and other emerging targets remains exploratory. A negative plasma circulating tumor DNA result does not exclude resistant disease, particularly in low-volume, peritoneal, or central nervous system progression.

Conclusion

Management should remain individualized and multidisciplinary, with explicit recognition that the proposed framework is provisional and that a survival benefit from local therapy with systemic treatment continuation remains unproven.